Pfizer Limited Reports FY26 Annual Results: Revenue Rises to ₹2,519.65 Crore, Recommends ₹75 Final Dividend

Pfizer Limited convened a Board of Directors meeting on May 12, 2026, at which it approved the audited financial results for the year ended March 31, 2026, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 1.30 p.m. and concluded at 6.30 p.m. The results were audited by statutory auditors M/s. B S R & Co., LLP, whose audit opinion carries no modifications.

Financial Performance Overview

Pfizer reported revenue from operations of ₹2,519.65 crore for the year ended March 31, 2026, compared to ₹2,281.35 crore in the previous year. Total income, including other income of ₹187.95 crore, stood at ₹2,707.60 crore versus ₹2,453.60 crore in FY25. Net profit for the year was ₹722.43 crore, compared to ₹767.60 crore in the prior year, with the variance partly attributable to exceptional items. The following table summarises the key financial metrics:

Metric: FY26 (Audited) FY25 (Audited) Revenue from Operations: ₹2,519.65 crore ₹2,281.35 crore Other Income: ₹187.95 crore ₹172.25 crore Total Income: ₹2,707.60 crore ₹2,453.60 crore Total Expenses: ₹1,682.77 crore ₹1,610.32 crore Profit Before Tax & Exceptional Items: ₹1,024.83 crore ₹843.28 crore Exceptional Items: ₹(49.16) crore ₹172.81 crore Profit Before Tax: ₹975.67 crore ₹1,016.09 crore Net Profit: ₹722.43 crore ₹767.60 crore Total Comprehensive Income: ₹726.27 crore ₹768.34 crore Basic & Diluted EPS (₹): ₹157.92 ₹167.79 EPS Before Exceptional Items (₹): ₹165.88 ₹136.46

Quarterly Performance

For the quarter ended March 31, 2026, Pfizer reported revenue from operations of ₹629.23 crore and net profit of ₹199.82 crore. Profit before tax and exceptional items for the quarter stood at ₹259.78 crore. The following table presents the quarterly comparison:

Metric: Q4 FY26 (Audited) Q3 FY26 (Unaudited) Q4 FY25 Revenue from Operations: ₹629.23 crore ₹645.03 crore ₹591.91 crore Total Income: ₹669.95 crore ₹683.24 crore ₹636.49 crore Total Expenses: ₹410.17 crore ₹433.09 crore ₹383.50 crore Profit Before Tax & Exceptional Items: ₹259.78 crore ₹250.15 crore ₹252.99 crore Net Profit: ₹199.82 crore ₹141.84 crore ₹330.94 crore

Exceptional Items

Exceptional items for FY26 amounted to a net charge of ₹49.16 crore. This comprised a charge of ₹41.73 crore towards personnel separation costs for field force and marketing teams, arising from an exclusive Supply and Marketing Agreement with Cipla Limited for marketing and distribution of four brands — Corex Dx, Corex LS, Dolonex, and Neksium — along with separation costs for other support functions. Additionally, a provision of ₹7.43 crore was recorded following the Company's assessment of the impact of the New Labour Codes, effective November 21, 2025, which consolidated several existing labour laws into four unified Labour Codes. In FY25, exceptional items represented a net gain of ₹172.81 crore from the assignment of a lease of MIDC Land and sale of the building constructed thereon.

Balance Sheet and Cash Flow Highlights

As at March 31, 2026, total assets stood at ₹4,921.88 crore compared to ₹4,911.11 crore as at March 31, 2025. Total equity was ₹4,202.90 crore, comprising equity share capital of ₹45.75 crore and other equity of ₹4,157.15 crore. Net cash generated from operating activities for FY26 was ₹967.57 crore, compared to ₹659.75 crore in FY25. Cash and cash equivalents at the end of the year were ₹102.66 crore, against ₹495.07 crore at the beginning of the year, reflecting net cash used in investing activities of ₹561.67 crore and net cash used in financing activities of ₹798.31 crore, which included dividend payments of ₹751.64 crore.

Dividend, AGM, and Other Corporate Developments

The Board recommended a final dividend of ₹75 per equity share of ₹10 each (750%) for the financial year ended March 31, 2026. The proposed dividend amounts to ₹343.11 crore and is subject to shareholder approval at the ensuing Annual General Meeting. The record date for the dividend has been set as Friday, July 17, 2026, and payment is scheduled on or after August 4, 2026. The 75th Annual General Meeting of the Company is scheduled for Tuesday, July 28, 2026, to be held via Video-Conferencing / Other Audio-Visual Means.

The Board also appointed M/s. Kishore Bhatia & Associates (Firm Registration No. 000294) as Cost Auditors for the financial year ending March 31, 2027, upon the recommendation of the Audit Committee. The remuneration payable to the firm will be placed before shareholders for ratification at the AGM. The Company confirmed that it does not fall under the category of a Large Corporate as at March 31, 2026, as it has not issued any debt securities, does not have outstanding long-term borrowings exceeding ₹1,000 crore, and has not obtained any credit ratings relating to borrowings. Pfizer operates solely in the Pharmaceuticals segment, and accordingly, no segment-wise disclosures are applicable.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.